Aspire Biopharma closes $30M Dura acquisition and layers in $3.75M convertible note financing
ASBP has more than doubled off its 52-week low of $3.309 on light trading volume (0.1× avg).
Summary
Aspire Biopharma closed its $30M acquisition of Dura Driver Control Systems, adding $200M+ in revenue, and disclosed a $3.75M convertible note issuance with a 20% OID and $8.00 conversion price, alongside a new $22.5M credit facility.
Key Events · M&A and Partnerships · ASBP
-
Acquisition Closed
Completed the $30 million cash acquisition of Dura Driver Control Systems, a global automotive supplier with $209.5M in FY2025 revenue and $22.3M in Adjusted EBITDA.
-
Convertible Note Financing
Issued $3.75M in secured convertible notes for $3.0M in proceeds (20% OID), convertible at $8.00 per share—near the current $7.98 stock price—with a six-month maturity and potential for additional OID increases.
-
Credit Facility Secured
Entered a $22.5 million senior secured revolving credit facility to fund the acquisition, supplementing cash on hand.
-
Transformative Scale Added
The acquisition adds 11 global manufacturing facilities, over 275 distinct parts, 310+ patents, and a blue-chip customer base with average 28-year relationships, immediately diversifying Aspire beyond biopharma.
Analysis · ASBP · Life Sciences
The $30 million acquisition of Dura Driver Control Systems—a tier-one automotive supplier generating over $200 million in annual revenue—is now complete. To fund the transaction, the company secured a $22.5 million senior secured revolving credit facility and issued $3.75 million in convertible notes with a 20% original issue discount, convertible at $8.00 per share, just above the current $7.98 stock price. The notes come with aggressive terms: a six-month maturity, the 20% OID, and the potential for additional 5% monthly OID increases if extended. While the deal transforms Aspire into a diversified, high-revenue enterprise, the convertible note financing introduces near-term dilution risk and reflects tight capital conditions. The acquisition immediately adds scale and cash flow, but the financing structure warrants close attention.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.8% of the 988 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ASBP was trading at $7.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.3M. The 52-week trading range was $3.31 to $1,050.36. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.